Abeona Therapeutics Inc. Quarterly report pursuant to Section 13 or 15(d)

Stock Based Option Compensation and Restricted Stock Compensation (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Share-based and Restricted Stock Compensation Expense [Abstract]
Stock-based compensation expense included in operating expense			$ 7,072,000	$ 3,527,000
Stock Options [Member]
Share-based and Restricted Stock Compensation Expense [Abstract]
Stock-based compensation expense included in operating expense	$ 2,499,000	$ 792,000	7,072,000	3,527,000
Stock Options [Member] \| Research and Development Expense [Member]
Share-based and Restricted Stock Compensation Expense [Abstract]
Stock-based compensation expense included in operating expense	1,012,000	394,000	2,756,000	1,118,000
Stock Options [Member] \| General and Administrative [Member]
Share-based and Restricted Stock Compensation Expense [Abstract]
Stock-based compensation expense included in operating expense	1,487,000	398,000	4,316,000	2,409,000
Restricted Stock [Member]
Share-based and Restricted Stock Compensation Expense [Abstract]
Stock-based compensation expense included in operating expense	172,000	293,000	516,000	979,000
Restricted Stock [Member] \| General and Administrative [Member]
Share-based and Restricted Stock Compensation Expense [Abstract]
Stock-based compensation expense included in operating expense	$ 172,000	$ 293,000	$ 516,000	$ 979,000